This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Researchers Prevent And Reverse Fibrosis In A Mouse Model Of Stiff Skin Syndrome; Study Shows Promise For Scleroderma

SAN FRANCISCO, Oct. 9, 2013 /PRNewswire-USNewswire/ -- The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy. In a report to be published online on October 10th in Nature, scientists show that integrin-modulating agents can arrest fibrosis in a model of scleroderma-like skin fibrosis and, more strikingly, that established fibrosis can be resolved with such agents. Although years away from an approved drug, the conclusion stands in sharp contrast to traditional thinking about scleroderma's irreversible advance and its resistance to therapeutic intervention. The Scleroderma Research Foundation has supported the work for the past six years. 

Systemic sclerosis (commonly referred to as scleroderma) is a rare autoimmune disease affecting approximately 1 in 4,000 Americans. A signature symptom is fibrosis of the skin, although the disease typically affects the lungs, kidneys and other organs with life-threatening consequences. Like many complex, adult-onset  autoimmune diseases, animal models replicate some, but not all features of the disease. This gap has slowed work in the scleroderma field. 

In the Nature report, a group led by Hal Dietz, M.D., focused on a genetic fibrotic disease called Stiff Skin Syndrome to provide insights. Dr. Dietz is a Professor of Genetics at The Johns Hopkins University School of Medicine, Director of the William S. Smilow Center for Marfan Syndrome Research and an Investigator for the Howard Hughes Medical Institute. "We looked to Stiff Skin Syndrome, an ultra-rare form of inherited scleroderma-like skin fibrosis as a means to understand the very similar skin fibrosis of systemic sclerosis," explains Dietz. "Reasoning that if we could understand how a single point mutation in the fibrillin-1 (FBN1) protein causes skin fibrosis in Stiff Skin Syndrome (SSS), this would help us to understand the biological pathways involved in systemic sclerosis, a typically acquired, adult-onset autoimmune disease." 

"There may be a final common pathway by which cells lose their normal control," postulates Dietz, "and even if one condition is genetic and the other is not, they may both funnel down to the same mechanism."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs